Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Nab-paclitaxel + Gemcitabine in Metastatic Pancreatic Cancer
NCT04498689Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, sponsored by Fudan University. Status: unknown.
02
Drugs
camrelizumab
Beyond the preview
Go deeper on NCT04498689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498689.